That partial hold on Gilead's $5B cancer drug? It's worse than we were initially told
Gilead’s trouble with its $5 billion drug magrolimab is considerably worse than it disclosed in a press release last week.
Originally, the big biotech alerted investors that they had to slam the brakes on enrolling patients in a slate of clinical trials that combined the CD47 drug magrolimab with azacitidine (Vidaza). That came after the agency flagged an “apparent imbalance” in the suspected unexpected serious adverse reactions between study arms.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
